Berlin – A Team led by partner Martin Schaper provided comprehensive legal and tax advice to a consortium of investors led by INKEF Capital on the investment in the Series B financing round of Hanover-based Cardior Pharmaceuticals. The round has a volume of € 64 million. In addition to lead investor INKEF, new investors Fund+, Sunstone, Hadean Ventures and Coparion participated in the round. In addition, existing investors such as LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds also participated in the financing round. In connection with the financing, representatives from INKEF Capital, Fund+ and Sunstone will join the company’s advisory board. Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program and the expansion of the company’s earlier-stage pipeline.
INKEF Capital is an Amsterdam-based venture capital firm backing promising early-stage companies in Europe with a portfolio of more than 45 companies in the healthcare and technology sectors.
Download PDF
Team:
Dr. Martin Schaper (Lead), Partner
Dr. Malte Bergmann, Partner
Dr. Martyna Sabat, Senior Associate
Dr. Ansgar Frank, Associated Partner
Ann-Kristin Lochmann, Senior Associate
Pia Meven, Associate
Jonas Huth, Associate
Lukas Schmitt, Associate
The law firm KNPZ (Dr. Kai Plath, Matthias Struck and Jan Schäfer) advised on the transaction alongside the YPOG Team on IP aspects.
About us
YPOG stands for You + Partners of Gamechangers – forward-thinking legal and tax advice. Supporting companies that are focused on emerging technologies, YPOG embraces change as an opportunity to develop cutting-edge solutions. The YPOG team offers comprehensive expertise in the areas of Funds, Tax, Transactions, Corporate, Banking, Regulatory + Finance, IP/IT/Data Protection, Litigation, and Corporate Crime + Compliance + Investigations. YPOG is one of the leading law firms in Germany for venture capital, private equity, fund structuring, and the implementation of distributed ledger technology (DLT) in financial services. Both the firm and its partners are regularly recognized by renowned national and international publications such as JUVE, Best Lawyers, Chambers and Partners, Leaders League, and Legal 500. YPOG is home to more than 150 experienced attorneys, tax advisors and tax specialists as well as a notary, working across offices in Berlin, Hamburg, Cologne, and Munich.
Further information: www.ypog.law/en/ and www.linkedin.com/company/ypog
